{
    "nctId": "NCT02321839",
    "officialTitle": "Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.",
    "inclusionCriteria": "* Signed informed consent form\n* Male or female of aged 50 years or older\n* Typical AMD and PCV patients\n* BCVA of 24 letters or over\n* Must have minimum age of 50 Years",
    "exclusionCriteria": "* Total lesion area of \\>12 DA or \\>30.5 mm2\n* The existence of subretinal hemorrhage area constituting \u226550% of total lesion area\n* The existence of scar or fibrosis area constituting \u226550% of total lesion area\n* The existence of RPE tear\n* Prior treatment for wet AMD\n* History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD\n* The pregnant or lactating woman"
}